Refreshing results…
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy
UploadTargeting BCL-XL in fibrolamellar hepatocellular carcinoma
Download from doi.orgOvercoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL–Specific Degrader DT2216
UploadTherapy-Induced Senescence: Opportunities to Improve Anticancer Therapy
Download from academic.oup.comProteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells
Download from www.nature.comA selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
UploadMissing publications? Search for publications with a matching author name.